 DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of its public offering of 6,000,000 ordinary shares or pre-funded warrants in lieu thereof at an effective offering price to the public of 2.50 per share or pre-funded warrant. 